Skip to contentpdufa.bio

Tividenofusp alfa

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

Tividenofusp alfa is a Denali Therapeutics Inc. program in hunter syndrome (MPS II). Its next catalyst is a Readout in Q2 2028.

DNLI catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Hunter syndrome (MPS II). Sponsor: Denali Therapeutics Inc. (DNLI). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q2 2028DNLI

Specialist biotech funds holding DNLI, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
Baker Bros. Advisors3,734,336$77.2 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is Tividenofusp alfa's next FDA decision or readout?

The next tracked catalyst for Tividenofusp alfa is a Readout in Q2 2028.

What happened at Tividenofusp alfa's most recent FDA decision?

No FDA decision for Tividenofusp alfa is in our archive yet.

What is Tividenofusp alfa used for?

In our records Tividenofusp alfa is under review or in development for Hunter syndrome (MPS II).

Who makes Tividenofusp alfa?

Denali Therapeutics Inc. (DNLI).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.